Glioblastoma Pipeline 2024: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic Therapeutics, Autotelic

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Glioblastoma pipeline constitutes 180+ key companies continuously working towards developing 200+ Glioblastoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Glioblastoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Glioblastoma Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Glioblastoma Market.

Some of the key takeaways from the Glioblastoma Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Glioblastoma treatment therapies with a considerable amount of success over the years.

*
Glioblastoma companies working in the treatment market are Denovo BioPharma, Apogenix, Cantex, VAXIMM, Mustang Bio, J INTS BIO, Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biopharm, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis, Denovo Biopharma, Celgene Corporation, and others, are developing therapies for the Glioblastoma treatment

*
Emerging Glioblastoma therapies in the different phases of clinical trials are- Enzastaurin, Asunercept, Azeliragon, VXM01, MB-101, JIN 001, CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, and others are expected to have a significant impact on the Glioblastoma market in the coming years.

*
In November 2024, Shuttle Pharma, a Maryland-based drug discovery company, has announced the expansion of its Phase II trial for ropidoxuridine, a potential treatment for glioblastoma, as the first cohort begins dosing at cancer centers across the United States. Ropidoxuridine is being evaluated in combination with radiation therapy to treat glioblastoma, an aggressive form of brain cancer. According to the National Brain Tumor Society, glioblastoma affects approximately 10,000 Americans annually, with a survival rate of just 6.9%.

*
In October 2024, Shuttle Pharmaceuticals (Shuttle Pharma) has administered the initial doses of its lead therapy, Ropidoxuridine, to the first three participants in a Phase II trial targeting glioblastoma, a type of brain cancer. Ropidoxuridine, a radiation sensitizer, is intended for use in combination with radiation therapy (RT) to treat the disease. The trial is focused on enrolling patients with isocitrate dehydrogenase (IDH) wild-type, methylation-negative glioblastoma.

*
In September 2024, Adaptin Bio announced that the FDA has approved the initiation of Phase 1 clinical trials for its APTN-101 program, which targets glioblastoma, the most prevalent and aggressive type of brain cancer.

*
In July 2024, Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, has announced results from the GBM-AGILE phase II/III study, which assessed paxalisib in comparison to the standard of care (SOC) for patients with glioblastoma, a severe form of brain cancer with a critical need for new treatments. The trial, registered under NCT03522298, aimed to address the urgent therapeutic gap for this life-threatening condition.

*
In July 2024, The Ivy Brain Tumor Center at Barrow Neurological Institute in the US has initiated dosing for the first participant in the Phase III Gliofocus clinical trial, which is evaluating niraparib, a selective PARP1/2 inhibitor, in adults with newly diagnosed MGMT-unmethylated glioblastoma. This open-label, randomized trial will compare the efficacy of niraparib against temozolomide, the current standard-of-care first-line chemotherapy. Supported by GSK, the trial will include 450 participants across more than 100 clinical sites in 11 countries.

*
In May 2024, Moleculin Biotech has announced the launch of an investigator-initiated Phase II NU 21C06 clinical trial, supported by funding from the National Institutes of Health (NIH), to evaluate WP1066 in combination with radiation therapy for adults with glioblastoma.

*
In February 2024, The Institute of Cancer Research (ICR) in London has reported encouraging results from a Phase I/II clinical trial of 2-OHOA, a new drug derived from oleic acid, for the treatment of glioblastoma. Oleic acid, found naturally in animal and vegetable fats like olive oil, is the basis for 2-OHOA, a synthetic lipid designed to inhibit cancer cell growth by restructuring their abnormal membranes.

Glioblastoma Overview

Glioblastoma, also known as glioblastoma multiforme (GBM), is a type of malignant brain tumor that arises from astrocytes, a type of supportive cells in the brain. It is the most aggressive and common form of primary brain cancer in adults. Glioblastomas are highly infiltrative tumors, meaning they spread rapidly and invade surrounding brain tissue, making complete surgical removal difficult.

Get a Free Sample PDF Report to know more about Glioblastoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight [https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Glioblastoma Drugs Under Different Phases of Clinical Development Include:

*
Enzastaurin: Denovo BioPharma

*
Asunercept: Apogenix

*
Azeliragon: Cantex

*
VXM01: VAXIMM

*
MB-101: Mustang Bio

*
JIN 001: J INTS BIO

*
CT 179: Curtana Pharmaceuticals

*
PRT3645: Prelude Therapeutics

*
CD200AR L: OX2 Therapeutics

*
ADI-PEG 20: Polaris Group

*
CM93: Crimson Biopharm

*
Berubicin: CNS Pharmaceuticals

*
SurVaxM: MimiVax

*
BPM31510: Berg, LLC

*
ASC40: Ascletis

*
Enzastaurin: Denovo Biopharma

*
Marizomib: Celgene Corporation

Glioblastoma Route of Administration

Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Glioblastoma Molecule Type

Glioblastoma Products have been categorized under various Molecule types, such as

*
Recombinant fusion proteins

*
Small molecule

*
Monoclonal antibody

*
Peptide

*
Polymer

*
Gene therapy

Glioblastoma Pipeline Therapeutics Assessment

*
Glioblastoma Assessment by Product Type

*
Glioblastoma By Stage and Product Type

*
Glioblastoma Assessment by Route of Administration

*
Glioblastoma By Stage and Route of Administration

*
Glioblastoma Assessment by Molecule Type

*
Glioblastoma by Stage and Molecule Type

DelveInsight's Glioblastoma Report covers around 200+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Glioblastoma product details are provided in the report. Download the Glioblastoma pipeline report to learn more about the emerging Glioblastoma therapies [https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Glioblastoma Therapeutics Market include:

Key companies developing therapies for Glioblastoma are - Array Biopharma, AstraZeneca, Doule bond Pharmaceuticals, Philogen, Immatics N.V, BioNTech, InovioPharma, Noxxon Pharma, Celgene Corporation, Karyo Pharma, Neugate Theranostics, Novartis, Orphelia Pharma, Merck, Acerta Pharma, Genenta Science, CNS Pharmaceutical, Pfizer, Roche, Oncotelic Therapeutics, Autotelic Therapeutics, ACADIA Pharmaceuticals, Mayo Clinic, Cytogel, Xgene Pharmaceutical, Ascletis, 3-V Biosciences, Yumanity Therapeutics, and others.

Glioblastoma Pipeline Analysis:

The Glioblastoma pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Glioblastoma with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioblastoma Treatment.

*
Glioblastoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioblastoma market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Glioblastoma drugs and therapies [https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Glioblastoma Pipeline Market Drivers

*
Rising incidence of Glioblastoma multiforme, improving Healthcare Infrastructure, demand for New and Effective Drugs are some of the important factors that are fueling the Glioblastoma Market.

Glioblastoma Pipeline Market Barriers

*
However, aggressive nature of GBM and the complexity of targeting the central nervous system, the current standard of care for patients with newly diagnosed glioblastoma has limited effectiveness and a second line has not been established and other factors are creating obstacles in the Glioblastoma Market growth.

Scope of Glioblastoma Pipeline Drug Insight

*
Coverage: Global

*
Key Glioblastoma Companies: Denovo BioPharma, Apogenix, Cantex, VAXIMM, Mustang Bio, J INTS BIO, Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biopharm, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis, Denovo Biopharma, Celgene Corporation, and others

*
Key Glioblastoma Therapies: Enzastaurin, Asunercept, Azeliragon, VXM01, MB-101, JIN 001, CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, and others

*
Glioblastoma Therapeutic Assessment: Glioblastoma current marketed and Glioblastoma emerging therapies

*
Glioblastoma Market Dynamics: Glioblastoma market drivers and Glioblastoma market barriers

Request for Sample PDF Report for Glioblastoma Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Glioblastoma Report Introduction

2. Glioblastoma Executive Summary

3. Glioblastoma Overview

4. Glioblastoma- Analytical Perspective In-depth Commercial Assessment

5. Glioblastoma Pipeline Therapeutics

6. Glioblastoma Late Stage Products (Phase II/III)

7. Glioblastoma Mid Stage Products (Phase II)

8. Glioblastoma Early Stage Products (Phase I)

9. Glioblastoma Preclinical Stage Products

10. Glioblastoma Therapeutics Assessment

11. Glioblastoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Glioblastoma Key Companies

14. Glioblastoma Key Products

15. Glioblastoma Unmet Needs

16 . Glioblastoma Market Drivers and Barriers

17. Glioblastoma Future Perspectives and Conclusion

18. Glioblastoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glioblastoma-pipeline-2024-indepth-clinical-trials-analysis-and-emerging-therapies-report-by-delveinsight-inoviopharma-pfizer-roche-acadia-pharma-biontech-oncotelic-therapeutics-autotelic]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.